APNS Discusses Diagnosing Alzheimer's Disease on CEOcast Today.Business Editors VERNON HILLS, Ill.--(BUSINESS WIRE)--Dec. 10, 2003 Applied NeuroSolutions, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :APNS APNS All Pakistan Newspapers Society APNS Alliance to Protect Nantucket Sound ) headquartered here, a world leader in the diagnosis of Alzheimer's disease, today announced its senior management is currently featured in an online interview with CEOcast.com. During the interview, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Bruce N. Barron and President and COO Dr. John F. DeBernardis presented an update on the company's progress in developing a cerebrospinal fluid (CSF Cerebrospinal Fluid (CSF) Analysis Definition Cerebrospinal fluid (CSF) analysis is a laboratory test to examine a sample of the fluid surrounding the brain and spinal cord. ) test to detect Alzheimer's disease at a very early stage with 85%-95% sensitivity and specificity. The CSF test, which distinguishes between Alzheimer's and other related disorders, such as depression, stroke and Parkinson's, is expected to begin pivotal clinical trials during the first quarter of calendar 2004. Management also discussed a second-stage, serum-based screening test that is also in an advanced stage of development. The interview is available at http://www.ceocast.com To access it, just click where it says "Register Free" in the upper right corner. About Applied NeuroSolutions In partnership with a team of distinguished scientists at Albert Einstein College of Medicine
The Albert Einstein College of Medicine (AECOM) is a graduate school of Yeshiva University. It is a private medical school located in the Jack and Pearl Resnick Campus of Yeshiva University in the Morris Park , Applied NeuroSolutions (OTCBB:APNS) is developing an integrated product portfolio for the diagnosis and treatment of Alzheimer's disease (AD). The company recently signed research agreements with Pfizer, Inc. (NYSE NYSE See: New York Stock Exchange :PFE 1. (text, editor) PFE - Programmer's File Editor. 2. (language) PFE - Portable Forth Environment. ) and Novartis AG (NYSE:NVS NVS - Non-Volatile Storage ) and expects to enter pivotal clinical trials with its lead diagnostic product in Q1 2004. About CEOcast CEOcast produces original and syndicated streaming broadcast interviews of chief executive officers at public and private news-making companies and distributes its programming to millions of online investors at over 700 financial web sites as well as to more than 20,000 portfolio managers, buy-side analysts and traders at more than 3,300 North American institutions. Content is also disseminated to over 7,000 investment research professionals representing over 425 institutions. This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the need to raise substantial additional equity capital, and the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, and potential competitive offerings. For further information, please visit the company's new website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion